Alvotech (ALVO) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Taysha Gene Therapies (TSHA) has outperformed Alvotech (ALVO) over the past year, losing 11.2% versus a loss of 19.8%. Alvotech is the larger company by market cap ($1.47 billion vs $1.21 billion), about 1.2 times the size. Alvotech converts more of its revenue into profit, with a net margin of 4.8% versus -1115.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALVO | TSHA |
|---|---|---|
| Share price | $4.12 | $3.72 |
| Market cap | $1.47B | $1.21B |
| 1-day change | -3.96% | -1.33% |
| YTD return | -19.69% | -32.36% |
| 1-year return | -19.84% | -11.22% |
| 5-year return | — | -70.69% |
| Forward P/E | 19.46 | — |
| EPS (TTM) | $-0.82 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $586.32M | $9.77M |
| Revenue growth (YoY) | +19.74% | +17.28% |
| Net income (latest FY) | $27.92M | $-109.00M |
| Gross margin | 59.82% | — |
| Operating margin | 13.34% | -1130.65% |
| Net margin | 4.76% | -1115.27% |
| 52-week high | $6.53 | $7.30 |
| 52-week low | $2.94 | $3.46 |
| Distance from 52-week high | -36.91% | -49.04% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +82.04% | +249.46% |
| Average volume | 1.13M | 3.59M |
| Shares outstanding | 356.82M | 326.05M |
| Employees | 1,279 | 99 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alvotech is more profitable, keeping 4.8 cents of every revenue dollar as net income versus -1115.3 cents for Taysha Gene Therapies.
About Alvotech
ALVO stock →Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 99 employees
ALVO vs TSHA FAQ
Which is bigger, Alvotech or Taysha Gene Therapies?
Alvotech (ALVO) is larger, with a market capitalization of $1.47B compared with $1.21B for Taysha Gene Therapies (TSHA).
Which stock has performed better over the past year, ALVO or TSHA?
TSHA returned -11.22% over the past 12 months, compared with -19.84% for ALVO (price return, excluding dividends). Past performance does not predict future results.
Are Alvotech and Taysha Gene Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.